Your session is about to expire
← Back to Search
Crenolanib + Chemotherapy for Acute Myeloid Leukemia
Study Summary
This trial is testing a new drug for people with a certain type of leukemia who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 & 2 trial • 16 Patients • NCT02626338Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have severe liver disease.I have never been treated with crenolanib or been in a crenolanib study.My AML did not respond or has returned after initial treatments.My liver is working well.I have been diagnosed with AML according to WHO standards.My kidney function is normal.I have active leukemia in my brain or spinal cord.I have an active hepatitis B or C infection.I am capable of limited self-care.I haven't had leukemia treatment in the last 14 days, except for hydroxyurea.I am between 18 and 75 years old.My cancer has a specific genetic mutation (FLT3-ITD or D835).
- Group 1: Crenolanib
- Group 2: Placebo
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are the findings of this Crenolanib study unique, or has this drug been researched before?
"At this time, there are 715 ongoing clinical trials researching Crenolanib with 99 in Phase 3. A notable amount of these clinical trials for Crenolanib are based in Saint Louis, Missouri, but there are15465 locations operating clinical trials for Crenolanib globally."
For what purpose is Crenolanib typically prescribed?
"Crenolanib is most often prescribed as a lymphoma treatment, but it can also be used to manage multiple sclerosis, infection, and help patients recover from bone marrow transplantation."
Has Crenolanib been given the green light by the FDA?
"Crenolanib has received a 3 for safety from our team at Power. This is due to the fact that it is a Phase 3 trial, thus having both some evidence of efficacy as well as multiple rounds of data affirming its safety."
Is this research project taking place in more than one hospital in this state?
"To limit participant burden, the10 sites for this clinical trial are located in or near major cities including Detroit, Winston-Salem and Chicago."
Are there any active vacancies in this research program?
"This medical trial is currently recruiting patients, as noted on the clinicaltrials.gov website. The trial was first posted on June 5, 2018 and was last updated on April 28, 2021."
Are there any conditions which would disqualify a patient from participating in this trial?
"Researchers are looking for 322 individuals with myeloid leukemia that fall between 18-75 years old. The most pertinent inclusion criteria are that patients have an ECOG performance status of 3 or less and are of age."
Will elderly individuals be included in this research?
"Those who meet the age requirements of 18-75 years old are able to participate in this clinical trial."
Share this study with friends
Copy Link
Messenger